Premium
Cancer Theranosis: Multimodal Cancer Theranosis Using Hyaluronate‐Conjugated Molybdenum Disulfide (Adv. Healthcare Mater. 1/2019)
Author(s) -
Shin MyeongHwan,
Park EunYeong,
Han Seulgi,
Jung Ho Sang,
Keum Do Hee,
Lee GeonHui,
Kim Taeyeon,
Kim Chulhong,
Kim Ki Su,
Yun Seok Hyun,
Hahn Sei Kwang
Publication year - 2019
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201970002
Subject(s) - conjugate , conjugated system , molybdenum disulfide , photothermal therapy , materials science , nanotechnology , combinatorial chemistry , chemistry , polymer , metallurgy , mathematical analysis , mathematics , composite material
In article number 1801036 , Ki Su Kim, Sei Kwang Hahn, and co‐workers develop hyaluronate conjugated molybdenum disulfide (HA‐MoS 2 conjugate) for targeted cancer theranosis. The HA‐MoS 2 conjugate can be successfully used for both photoacoustic and fluorescence imaging. In addition, upon NIR light illumination, HA‐MoS 2 conjugate enables highly effective target‐specific photothermal cancer therapy. Taken together, HA‐MoS 2 conjugate appears to show a great potential for various theranostic applications.